I studie NV17317 med patienter smittet med virologisk genotype 2 eller 3, modtog alle patienter Pegasys 180 μg s. c. én gang ugentlig og 800 mg ribavirin, og patienterne blev randomiceret til 16 eller 24 ugers behandling.
In study NV17317 in patients infected with viral genotype 2 or 3, all patients received Pegasys 180 μ g sc qw and a ribavirin dose of 800 mg and were randomized to treatment for either 16 or 24 weeks.